摘要
为了观察小剂量单药化疗对老年晚期非小细胞肺癌(NSCLC)的临床疗效,98例患者接受小剂量多西他赛单药化疗。按照多西他赛20mg/m2剂量加入250mL生理盐水,持续静脉滴入>1.5h,21d为1个周期,化疗>2个周期。参照Karnofsky生存质量评分和实体肿瘤疗效评价标准评定疗效,按照1981年WHO抗癌药物不良反应标准评定不良反应。结果:98例患者,CR1例(1.0%),PR35例(35.7%),SD56例(57.1%),PD6例(6.1%),其中CR+PR36例(36.7%)。治疗前Karnofsky评分为60～90,平均78.46±0.009;治疗后为70～100,平均82.85±0.007。治疗前后差异有统计学意义,t=4.39,P<0.05。初步研究结果提示,小剂量单药化疗减少或避免了不良反应,改善了患者的生活质量,延长了生存时间,应为老年晚期NSCLC的首选治疗方案。
The objective of this study was to investigate the clinical efficiency of low dose taxotere in the treatment of terminal non-small cell lung cancer （NSCLC） in aged patients. Ninety-eight aged patients with NSCLC received taxotere 20 mg/m^2 in 250 mL normal saline per day （iv drop〉1.5 h）, 21 days as one cycle and last at least 2 cycles. The efficiency was evaluated hy Karnofsky scale system and response evaluation criteria in solid tumors （RECIST）, and toxicities were evaluated according to the standard of WHO. Of all the 98 patients, there were CR 1 （1.0%）, PR 35 （35.7%）,SD 56 （57. 1%）,PD6 （6. 1%）, andCR ＋ PR36 （36.7%）. The Karnofsky scores were 60--90 （average 78.46±0. 009） before the treatment and 70-100 （ average 82.85±0. 007） after the treatment, t= 4.39, P〈0.05. In conclusion, the low dose single drug chemotherapy, which reduces the toxicities and improves the qualities of life, is the first choice to the aged patients with advanced NSCLC.
出处
《中华肿瘤防治杂志》
CAS
2009年第10期787-788,共2页
Chinese Journal of Cancer Prevention and Treatment
